Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 4/20 | 0.39 |
| ▸ | TYMP | P19971 | 4/20 | 0.37 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TK2 | O00142 | 3/20 | 0.31 |
| ▸ | PRKCA | P17252 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL727569 | 0.81 | TYMP (0.43) | TK1TYMPMAPK1 | |
| SCHEMBL2695188 | 0.81 | TK1 (0.39) | TK1TYMPRNASE1HPGDMAPK1 | |
| SCHEMBL18191112 | 0.79 | TK1 (0.47) | TK1TYMPRNASE1HPGDMAPK1 | |
| SCHEMBL18191114 | 0.78 | TK1 (0.41) | TK1RNASE1HPGDMAPK1TP53 | |
| SCHEMBL727552 | 0.73 | TYMP (0.52) | TK1TYMPMAPK1CTSK | |
| SCHEMBL18191119 | 0.72 | HDAC1 (0.35) | — | |
| SCHEMBL16177214 | 0.71 | NPC1 (0.39) | HPGDTP53TSHRPRKCA | |
| SCHEMBL13402547 | 0.71 | TK1 (0.51) | TK1TYMPRNASE1HPGDMAPK1 | |
| SCHEMBL725991 | 0.69 | PKM (0.33) | CTSK | |
| SCHEMBL725874 | 0.69 | TYMP (0.57) | TK1TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185062-A1 | Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2007-08-09 | — | — | US | claimed |
| US-10087209-B2 | Antiviral compounds, a process for their preparation, and their use for treating viral infections | KU LEUVEN RESEARCH & DEVELOPMENT (BE) | 2018-10-02 | — | — | US | disclosed |
| US-20180105552-A1 | NOVEL ANTIVIRAL COMPOUNDS, A PROCESS FOR THEIR PREPARATION, AND THEIR USE FOR TREATING VIRAL INFECTIONS | KU LEUVEN RESEARCH & DEVELOPMENT (BE) | 2018-04-19 | — | — | US | disclosed |
| US-9522932-B2 | Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2016-12-20 | — | — | US | disclosed |
| WO-2016174081-A1 | NOVEL ANTIVIRAL COMPOUNDS, A PROCESS FOR THEIR PREPARATION, AND THEIR USE FOR TREATING VIRAL INFECTIONS | KU LEUVEN RESEARCH & DEVELOPMENT (BE) | 2016-11-03 | — | — | WO | disclosed |
| EP-2980095-A1 | PHOSPONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | K.U.Leuven Research & Development (BE) | 2016-02-03 | — | — | EP | disclosed |
| US-9249177-B2 | Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2016-02-02 | — | — | US | disclosed |
| US-20160009750-A1 | PHOSPHONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2016-01-14 | — | — | US | disclosed |
| EP-1720890-B1 | PHOSPONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | LEUVEN K U RES & DEV (BE) | 2015-05-20 | — | — | EP | disclosed |
| US-20140316127-A1 | PHOSPHONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2014-10-23 | — | — | US | disclosed |
| US-8809520-B2 | Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2014-08-19 | — | — | US | disclosed |
| US-20140039179-A1 | PHOSPHONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2014-02-06 | — | — | US | disclosed |
| US-8501709-B2 | Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | K.U.LEUVEN RESEARCH & DEVELOPMENT (BE) | 2013-08-06 | — | — | US | disclosed |
| US-20120108531-A1 | PHOSPHONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | K.U.LEUVEN RESEARCH & DEVELOPMENT (BE) | 2012-05-03 | — | — | US | disclosed |
| US-8076310-B2 | Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | K.U.LEUVEN RESEARCH & DEVELOPMENT (BE) | 2011-12-13 | — | — | US | disclosed |
| US-20070185062-A1 | Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2007-08-09 | — | — | US | disclosed |
| EP-1750572-A2 | METHOD OF DETERMINING THE SYMPATHETIC TONE AND SYSTEM FOR MEASUREMENT THEREOF | Stressmeter A/S (DK) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005084529-A2 | METHOD OF DETERMINING THE SYMPATHETIC TONE AND SYSTEM FOR MEASUREMENT THEREOF | STRESSMETER A/S (DK) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140039179-A1 | PHOSPHONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | PNP, NUDT1, TYMP | TK1 20/4885TYMP 3/4885RNASE1 186/4885 |
| US-20120108531-A1 | PHOSPHONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | TYMP, PNP, NUDT1 | TK1 10/4885TYMP 1/4885RNASE1 702/4885 |
| US-20180105552-A1 | NOVEL ANTIVIRAL COMPOUNDS, A PROCESS FOR THEIR PREPARATION, AND THEIR USE FOR TREATING VIRAL INFECTIONS | TYMP, MTAP, PNP | TK1 32/4885TYMP 1/4885RNASE1 810/4885 |
| US-20070185062-A1 | Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | ENTPD5, PPA1, TYMP | TK1 44/4885TYMP 3/4885RNASE1 951/4885 |
| US-10087209-B2 | Antiviral compounds, a process for their preparation, and their use for treating viral infections | TYMP, PNP, MTAP | TK1 26/4885TYMP 1/4885RNASE1 746/4885 |
| US-20160009750-A1 | PHOSPHONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | PNP, NUDT1, TYMP | TK1 20/4885TYMP 3/4885RNASE1 186/4885 |
| US-20140316127-A1 | PHOSPHONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | PNP, NUDT1, TYMP | TK1 20/4885TYMP 3/4885RNASE1 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.